Skip to main content
Clinical Trials/NCT04028258
NCT04028258
Unknown
N/A

Randomized, Controlled, Crossover, Double-blind Clinical Trial on the Effect of a Mixture of Plant-based Fibers and Carbohydrates on Intestinal Transit in Children Aged 3 to 12 Diagnosed With Functional Constipation

Laboratorios Ordesa3 sites in 1 country120 target enrollmentFebruary 13, 2018

Overview

Phase
N/A
Intervention
Not specified
Conditions
Constipation - Functional
Sponsor
Laboratorios Ordesa
Enrollment
120
Locations
3
Primary Endpoint
Percentage of clinical change obtained from the difference between the initial value and the final value for a combined score of the frequency of passage of faeces, pain to defecation, consistency of stool.
Last Updated
6 years ago

Overview

Brief Summary

Once the patients who are candidates to enter the study are identified, the patients will be randomly be assigned to two groups, according to the sequence:

  • Group A: study product+wash out+control product
  • Group B: control product+wash out+study product

Detailed Description

All patients will be given guidelines for adopting dietary habits and healthy lifestyles to achieve a regular and physiological depositional rhythm and will be given a study supplement and a control supplement, alternatively, for 2 time periods of 3 weeks separated by 2 weeks of wash out. * Supplement under study: mixture of food fibers of plant origin, in a proportion that contributes 75% soluble fiber / 25% insoluble fiber. * Control: Placebo supplement: maltodextrin and plum flakes

Registry
clinicaltrials.gov
Start Date
February 13, 2018
End Date
December 2020
Last Updated
6 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Sponsor
Laboratorios Ordesa
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Boys and girls aged 3 to 12
  • Diagnosis of functional constipation according to Rome IV criteria

Exclusion Criteria

  • Regular use of a dietary fiber supplement, prebiotics or probiotics in the previous 30 days, or who would have been taking bulk-forming agents or laxatives in the 2 weeks prior to the study
  • Use of medications that cause constipation
  • Children with organic constipation such as Hirschsprung's disease, cerebral paralysis, anorectal and spinal cord abnormalities and metabolic diseases.
  • Patients who are not likely to complete follow-up

Outcomes

Primary Outcomes

Percentage of clinical change obtained from the difference between the initial value and the final value for a combined score of the frequency of passage of faeces, pain to defecation, consistency of stool.

Time Frame: From baseline to 8 weeks

Combined score between this parameters

Secondary Outcomes

  • Consistency of stool according to Bristol Stool Form Scale(From baseline to 8 weeks)
  • Frequency of stool(From baseline to 8 weeks)
  • Change in stool weight(From baseline to 8 weeks)
  • Patient anthropometric measures: waist perimeter(Up to 8 weeks)
  • Gastrointestinal symptoms related to the constipation(From baseline to 8 weeks)
  • Patient anthropometric measures: size(Up to 8 weeks)
  • Patient anthropometric measures: weight(Up to 8 weeks)
  • Adherence record to the complement intake (Moriski Green test)(At 8 weeks)

Study Sites (3)

Loading locations...

Similar Trials